Running a small business involves handling many responsibilities at once, including managing risk. Every business faces threats that could disrupt operations, affect finances or lead to legal ...

Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha ...

Background High-dose folic acid supplementation is recommended for women using antiseizure medication (ASMs) to reduce risk of major congenital anomalies (MCAs) in offspring, but evidence is lacking.

Thyme Care bets on ePRO-driven toxicity monitoring to cut Medicare oncology adverse events, infections and ED visits—making value-based care finally work. Whenever I start to wonder about the reason ...

Apixaban and rivaroxaban are the oral anticoagulants most frequently used to treat acute venous thromboembolism. However, uncertainty remains about the difference in bleeding risk between the two ...

New research finds that most countries are trending in the wrong direction when it comes to meeting the U.N.’s 2030 global pesticide risk reduction target, with the goal unlikely to be met without ...

For patients with type 2 diabetes, a new study reinforces the importance of adhering to a healthy lifestyle even when taking a glucagon-like peptide-1 (GLP-1) receptor agonist. Patients who combined a ...

The phase 3 ADVANCE OUTCOMES study of ralinepag met its primary endpoint and several important secondary endpoints, including increasing odds of clinical improvement by 47%, in predominantly ...

Please provide your email address to receive an email when new articles are posted on . Urate-lowering treatment reduced the 5-year risk for major adverse cardiovascular events for patients with gout.

Seres Therapeutics sold VOWST to Nestlé in 2024. This helped validate their microbiome therapeutics. This sale also helped them extend their runway into Q2 2026 after a 25% workforce reduction. Their ...

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and Johnson & Johnson’s rival factor XIa inhibitor in a blockbuster indication.